Global Markets for Treatments for Syndromes of Dementia and Movement Disorders

Global Markets for Treatments for Syndromes of Dementia and
Movement Disorders
Report Details:
Published:September 2012
No. of Pages: 228
Price: Single User License – US$4850

•The global market for treatments for syndromes of dementia and movement disorders was valued
at 10.5 billion in 2011 and should reach $11.1 billion in 2012. Total market value is expected to
reach $16.7 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR)
of 8.5%.
•Progressive dementia treatments are expected to have a value of $7.3 billion in 2012 and nearly
$11 billion in 2017, a CAGR of 8.4%.
•Treatments for movement disorders are expected to be worth $3.2 billion in 2012 and $4.8 billion
in 2017, a CAGR of 8.3%.
REPORT SCOPE

INTRODUCTION

STUDY OBJECTIVES

BCC’s goal in conducting this study is to provide an overview of the current and future
characteristics of the global markets for treatments for syndromes of dementia and movement
disorders. The key objective is to present a comprehensive analysis and the future direction of the
market as it shapes drug and therapy development.

This report explores present and future strategies within the neurodegenerative disorder market,
which includes treatments and therapies for progressive dementia, progressive dementia with
other neurological abnormalities and movement disorders. Market gains, setbacks and needs are
discussed in this report. Comparisons, usage and the advantages and disadvantages of different
types of technologies, including small molecules and monoclonal antibodies, are also presented in
this report.

A detailed analysis of the structure of the syndromes of dementia and movement disorder industry
has been conducted. Revenues are broken down by neurodegenerative disease and primary
clinical/pathological feature. Sales figures are estimated for the five-year period from 2012

through 2017.

Applications for syndromes of dementia and movement disorder treatments, or therapeutic
technologies, are also discussed separately in the report, with an emphasis on small molecule and
monoclonal antibodies technology. The report also covers significant patents and their allotment
in each category.

REASONS FOR DOING THIS STUDY

Extensive research in the field of syndromes of dementia and movement disorders and company
collaborations with research institutes have highlighted the importance of understanding the nature
of these disorders. New technological developments are providing disease-modifying therapies
for the late stages of the disorders. Collaborations between research institutes and pharmaceutical
companies are on the rise as state-of-the-art technology is being explored to develop more
efficient products and therapies.

R&D spending, along with increasing competition, patent expiries and new technologies are taking
the market in a new direction. Global market revenues increased from 2009 to 2011 and are
expected to continue to show growth over the forecast period as new advances, launches and
collaborations continue to influence the market. This study looks at most of the systems affected
by these factors.

Acquisition strategies and collaborations by companies are also covered in this report. This study
also discusses the strength and weaknesses of each type of technology in light of the new
technologies, growing competition and changing customer needs.

CONTRIBUTIONS OF THE STUDY AND FOR WHOM

This study contributes to the areas of market growth in treatments for Alzheimer’s disease, Lewy
body dementia, Pick’s disease, Huntington’s disease, corticobasal ganglionic degeneration,
Parkinson’s disease, multiple system atrophy, progressive supranuclear palsy and Hallervorden-
Spatz disease. Pharmaceutical biotechnical companies, research institutes and physicians will
find this study to be of interest.

SCOPE OF THE STUDY

The scope of this study encompasses the neurodegenerative disorders in the pharmaceutical and
biotechnology markets. BCC analyzes each market and its applications, regulatory environment,
technology involved, market projections and market share. Technological issues include the latest
trends and developments. The emerging market for enzyme inhibitors includes countries such as
India, China, Japan, Korea, Taiwan, Canada, Africa, Australia, New Zealand and Mexico.

METHODOLOGY

BCC conducted a comprehensive literature search, which included technical newsletters and
journals, and many other sources. Data were collected through interviews and correspondence
with manufacturers of enzyme inhibitors’ technical experts. Projections were based on estimates
such as the current number of end users, potential end users, mergers and acquisitions, and
market trends.

INFORMATION SOURCES

Many companies within the industry were surveyed to obtain data for this study. Included were
manufacturers and end users of enzyme inhibitors in therapeutic categories and various disease
sectors industries. Data were gathered from various industry sources. BCC spoke with officials
within the industry, consulted newsletters, company literature, product literature and a host of
technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key
terminology were completed. In addition, data were compiled from current financial, trade and
government sources.

Get your copy of this report @
http://www.reportsnreports.com/reports/195544-global-markets-for-treatments-for-syndromes-of-dementia-and-
movement-disorders.html

Major points covered in Table of Contents of this report include
Table Of Contents

Chapter- 1: Introduction - Complimentary 3
Study Objectives
Reasons For Doing This Study
Contributions Of The Study And For Whom
Scope Of The Study
Methodology
Information Sources
About The Author
Related Bcc Research Reports
Bcc Online Services
Disclaimer

Chapter- 2: Executive Summary 2
Table Summary : Global Market For Treatments For Syndromes Of Dementia And Movement
Disorders, Through 2017
Figure Summary : Global Market For Treatments For Syndromes Of Dementia And Movement
Disorders, 2010-2017

Chapter- 3: Overview 10
The Brain
Classification Of Neurodegenerative Disorders
Neurodegenerative Disorders
Diagnostic Tests For Neurodegenerative Disorders

Chapter- 4: Regulatory Aspects 5
Introduction
Drug Approvals
Regulatory Developments Affecting Syndromes Of Dementia And Movement Disorder Products

Chapter- 5: New Developments 19
Table 6 : New Developments In Drugs Used To Treat Syndromes Of Dementia And Movement
Disorders, 2012
Disorders, 2011
Disorders, 2010

Chapter- 6: Global Markets 13
Markets By Clinical/Pathological Feature
Market By Disease Type
Market By Region
Markets By Technology

Chapter- 7: Market For Drug Products Used To Treat Progressive Dementia 32
Market By Region
Regional Markets By Disease Type
Market By Technology
Industry Structure

Chapter- 8: Market For Drugs To Treat Progressive Dementia With Other Neurological
Abnormalities 24
Market By Region
Industry Structure

Chapter- 9: Market For Movement Disorder Syndromes 35

Market By Type Of Disease
Markets By Region
Industry Structure

Chapter- 10: Patent Analysis 20
Patents Issued By Year
Patents By Disease Category
Patents By Disease Type
Patents By Country
Patents By Company

Chapter- 11: Current Situation 7
Market Trends
Overall Drivers Of The Market For Treatments For Syndromes Of Dementia And Movement
Disorders
Other Factors Affecting The Market
Collaborations/Mergers And Acquisitions

Chapter- 12: Company Profiles 55
Abbott Laboratories
Ablynx Nv
Accera Inc.
Acorda Therapeutics Inc.
Actavis Elizabeth
Affiris Ag
Alliance Pharma Plc
Allon Therapeutics Inc.
Alphapharm
Alzhyme Ltd.
American Regent Inc.
Apotex Inc.
Apotheca Inc.
Astellas Pharma Inc.
Astrazeneca Gmbh
Aurobindo Pharma Ltd.
Baxter International Inc.
Bellus Health Inc.
Boehringer Ingelheim Ltd.
Bristol-Myers Squibb
Bryant Ranch Prepack

Cadila Healthcare Ltd.
Caraco Pharmaceutical Laboratories
Cardinal Health
Cellzome Ag
Cipla Ltd.
Cognition Therapeutics Inc.
Colucid Pharmaceuticals Inc.
Comentis Inc.
Cortex Pharmaceuticals
Cytos Biotechnology Ag
Daiichi Sankyo Co. Ltd.
Dr. Reddy's Laboratories Ltd.
Eisai Co. Ltd.
Elan Pharma International Ltd.
Eli Lilly And Co.
Endo Pharmaceuticals Inc.
Envivo Pharmaceuticals
Evotec Ag
Epitomics Inc.
Exonhit Therapeutics Sa
Forest Laboratories Inc.
Glaxosmithkline Plc
Glenmark Generics Ltd.
H. Lundbeck A/S
Hameln Pharmaceuticals Ltd.
Helicon Therapeutics Inc.
Hospira Inc.
Intellect Neurosciences Inc.
Intra-Cellular Therapies Inc.
Jazz Pharmaceuticals Plc
Major Pharmaceuticals
Medivation Inc.
Memory Pharmaceuticals Corp.
Merck Serono
Merck Sharp & Dohme Ltd.
Merz Pharma Gmbh & Co Kgaa
Mithridion Inc.
Mylan Pharmaceuticals
Neuren Pharmaceuticals Ltd.
Neuro-Hitech Inc.
Neuroptix Corp.
Neurosearch A/S

Newron Pharmaceuticals Spa
Noscira Sa
Novartis Ag
Nymox Pharmaceutical Corp.
Orchid Chemicals & Pharmaceuticals Ltd.
Orion Corp.
Ortho-Mcneil Janssen Pharmaceuticals Inc.
Par Pharmaceuticals
Perrigo Co.
Pfizer Inc.
Pharnext
Physicians Total Care Inc.
Pliva Hrvatska D.O.O.
Prasco Laboratories
Ranbaxy Laboratories Ltd.
Roche Holding Ltd.
Roxane Laboratories Inc.
Sandoz International Gmbh
Sanofi
Santhera Pharmaceuticals
Shionogi & Co.
Stada Arzneimittel Ag
Sun Pharma
Taj Pharmaceuticals Ltd.
Takeda Pharmaceutical Co. Ltd.
Tercica Inc.
Teva Pharmaceutical Industries Ltd.
Torrent Pharma
Ucb Sa
Udl Laboratories
Upsher-Smith Laboratories
Valeant Pharmaceuticals
Vernalis Plc
Watson Pharmaceuticals Inc.
West-Ward Pharmaceutical

Chapter- 13: Appendix I: Abbreviations 3

List Of Tables

Summary Table : Global Market For Treatments For Syndromes Of Dementia And Movement

Table 1 : Classification Of Syndromes Of Dementia And Movement Disorders By Primary
Clinical/Pathological Feature
Table 2 : Anda And Nda Approvals Of Drugs Used To Treat Syndromes Of Dementia And
Movement Disorders, 2010 To March 2012
Table 3 : Pending New Drug Applications For Drugs Used To Treat Syndromes Of Dementia And
Movement Disorders
Table 4 : Fda Drug Safety Alerts, 2010 To March 2012
Table 5 : Fda Recalls Of Drugs Used To Treat Syndromes Of Dementia And Movement Disorders,
2010 To March 2012
Disorders, 2012
Disorders, 2011
Disorders, 2010
Table 9 : Global Sales Of Drug Products Used To Treat Syndromes Of Dementia And Movement
Table 10 : Global Market Shares Of Drug Products Used To Treat Neurodegenerative Disorders
By Clinical/Pathological Feature, 2011
Table 11 : Global Sales Of Drug Products Used To Treat Major Neurodegenerative Disorders,
Through 2017
Table 12 : Global Market Shares Of Drug Products Used To Treat Syndromes Of Dementia And
Movement Disorders By Disease Type, 2011
Disorders By Region, Through 2017
Movement Disorders By Region, 2011
Disorders By Technology, Through 2017
Movement Disorders By Technology, 2011
Table 17 : Global Sales Of Drug Products Used To Treat Progressive Dementia, Through 2017
Table 18 : Global Market Shares Of Drug Products Used To Treat Progressive Dementia By
Disease Type, 2011
Table 19 : Global Sales Of Drug Products Used To Treat Progressive Dementia By Region,
Through 2017
Region, 2011
Table 21 : Global Sales Of Drug Products Used To Treat Alzheimer’s Disease By Region, Through
2017
Table 22 : Global Sales Of Drug Products Used To Treat Lewy Body Dementia By Region,
Through 2017

Table 23 : Global Sales Of Drug Products Used To Treat Pick’s Disease By Region, Through 2017
Table 24 : Global Sales Of Drug Products Used To Treat Progressive Dementia By Technology,
Through 2017
Technology, 2011
Table 26 : Leading Manufacturers/Distributors Of Drugs/Therapies Used To Treat Alzheimer's
Disease
Table 27 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat Alzheimer’s
Disease, 2011
Table 28 : Leading Manufacturers/Distributors Of Drugs/Therapies Used To Treat Lewy Body
Dementia
Table 29 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat Lewy Body
Dementia, 2011
Table 30 : Leading Manufacturers/ Distributors Of Drugs/Therapies Used To Treat Pick’s Disease
Table 31 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat Pick’s
Disease, 2011
Table 32 : Chdi Foundations’ Key Developments In Treating Huntington’s Disease
Table 33 : Global Sales Of Drug Products Used To Treat Progressive Dementia With Other
Neurological Abnormalities By Type Of Disease, Through 2017
Table 34 : Global Market Shares Of Drug Products Used To Treat Progressive Dementia With
Other Neurological Abnormalities By Disease Type, 2011
Neurological Abnormalities By Region, Through 2017
Other Neurological Abnormalities By Region, 2011
Table 37 : Global Sales Of Drug Products Used To Treat Huntington’s Disease By Region,
Through 2017
Table 38 : Global Sales Of Drugs Used To Treat Corticobasal Ganglionic Degeneration By
Region, Through 2017
Neurological Abnormalities By Technology, Through 2017
Other Neurological Abnormalities By Technology, 2011
Table 41 : Leading Manufacturers/Suppliers Of Drugs/Therapies Used To Treat Huntington’s
Disease
Table 42 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat Huntington's
Disease, 2011
Table 43 : Leading Manufacturers/Suppliers Of Drugs/Therapies Used To Treat Huntington’s
Disease
Table 44 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat Corticobasal
Ganglionic Degeneration, 2011
Table 45 : Global Sales Of Drug Products Used To Treat Movement Disorder Syndromes By

Disease Type, Through 2017
Table 46 : Global Market Shares Of Drug Products Used To Treat Movement Disorder Syndromes
By Disease Type, 2011
Table 47 : Global Sales Of Drugs Used To Treat Movement Disorder Syndromes By Region,
Through 2017
By Region, 2011
Table 49 : Global Sales Of Drug Products Used To Treat Parkinson’s Disease By Region, Through
2017
Table 50 : Global Sales Of Drug Products Used To Treat Multiple System Atrophy By Region,
Through 2017
Table 51 : Global Sales Of Drug Products Used To Treat Progressive Supranuclear Palsy By
Table 52 : Global Sales Of Drug Products Used To Treat Hallervorden-Spatz Disease By Region,
Through 2017
Table 53 : Global Sales Of Drug Products Used To Treat Movement Disorder Syndromes By
Technology, Through 2017
By Technology, 2011
Table 55 : Leading Manufacturers/Suppliers Of Drugs/Therapies Used To Treat Parkinson’s
Disease
Table 56 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat Parkinson’s
Disease, 2011
Table 57 : Leading Manufacturers/Distributors Of Drugs/Therapies Used To Treat Multiple System
Atrophy
Table 58 : Manufacturers/Distributor Market Shares Of Drug Products Used To Treat Multiple
System Atrophy, 2011
Table 59 : Leading Manufacturers/Suppliers Of Drugs/Therapies Used To Treat Progressive
Supranuclear Palsy
Table 60 : Manufacturers/Distributor Market Shares Of Drug Products Used To Treat Progressive
Supranuclear Palsy, 2011
Table 61 : Leading Manufacturers/Suppliers Of Drugs/Therapies Used To Treat Hallervorden-
Spatz Disease
Table 62 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat Hallervorden-
Spatz Disease, 2011
Table 63 : U.S. Patents On Drugs Used To Treat Syndromes Of Dementia And Movement
Disorders Issued Per Year, 2010-March 2012
Table 64 : U.S. Patents On Drugs Used To Treat Syndromes Of Dementia And Movement
Disorders By Category Of Disease, 2010-March 2012
Table 65 : U.S. Patents On Drugs Used To Treat Syndromes Of Dementia (Progressive Dementia)
By Clinical/Pathological Feature, 2010-March 2012
Table 66 : U.S. Patents On Drugs Used To Treat Movement Disorder Syndromes By Disease

Type, 2010-March 2012
Table 67 : U.S. Patents On Drugs Used To Treat Syndromes Of Dementia (Progressive Dementia)
By Patent Holder’s Country, 2010-March 2012
Table 68 : U.S. Patent Shares Of Drugs Used To Treat Progressive Dementia By Patent Holder’s
Country, 2010-March 2012
Table 69 : U.S. Patents On Drugs Used To Treat Movement Disorder Syndromes By Patent
Holder’s Country, 2010-March 2012
Table 70 : U.S. Patent Shares Of Drugs Used To Treat Movement Disorder Syndromes By Patent
Table 71 : Number Of U.S. Patents On Drugs Used To Treat Syndromes Of Dementia
(Progressive Dementia) By Company, 2010-March 2012
Table 72 : U.S. Patents On Drugs Used To Treat Movement Disorder Syndromes By Company,
2010-March 2012

List Of Figures

Summary Figure : Global Market For Treatments For Syndromes Of Dementia And Movement
Figure 1 : Global Sales Of Drug Products Used To Treat Syndromes Of Dementia And Movement
Figure 2 : Global Market Shares Of Drug Products Used To Treat Neurodegenerative Disorders
By Clinical/Pathological Feature, 2011
Figure 3 : Global Sales Of Drug Products Used To Treat Major Neurodegenerative Disorders,
2010-2017
Figure 4 : Global Market Shares Of Drug Products Used To Treat Syndromes Of Dementia And
Movement Disorders By Disease, 2011
Disorders By Region, 2010-2017
Movement Disorders By Region, 2011
Disorders By Technology, 2010-2017
Movement Disorders By Technology, 2011
Figure 9 : Global Sales Of Drug Products Used To Treat Progressive Dementia, 2010-2017
Figure 10 : Global Market Shares Of Drug Products Used To Treat Progressive Dementia By
Disease Type, 2011
Figure 11 : Global Sales Of Drug Products Used To Treat Progressive Dementia By Region, 2010-
2017
Region, 2011
Figure 13 : Global Sales Of Drug Products Used To Treat Alzheimer’s Disease By Region, 2010-

2017
Figure 14 : Global Sales Of Drug Products Used To Treat Lewy Body Dementia By Region, 2010-
2017
Figure 15 : Global Sales Of Drug Products Used To Treat Pick’s Disease By Region, 2010-2017
Figure 16 : Global Sales Of Drug Products Used To Treat Progressive Dementia By Technology,
2010-2017
Technology, 2011
Figure 18 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat Alzheimer’s
Disease, 2011
Figure 19 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat Lewy Body
Dementia, 2011
Figure 20 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat Pick’s
Disease, 2011
Figure 21 : Global Sales Of Drug Products Used To Treat Progressive Dementia With Other
Neurological Abnormalities By Type Of Disease, 2010-2017
Figure 22 : Global Market Shares Of Drug Products Used To Treat Progressive Dementia With
Other Neurological Abnormalities By Disease Type, 2011
Neurological Abnormalities By Region, 2010-2017
Other Neurological Abnormalities By Region, 2011
Figure 25 : Global Sales Of Drugs Used To Treat Huntington’s Disease By Region, 2010-2017
Figure 26 : Global Sales Of Drugs Used To Treat Corticobasal Ganglionic Degeneration By
Neurological Abnormalities By Technology, 2010-2017
Other Neurological Abnormalities By Technology, 2011
Figure 29 : Manufacturer/Distributor Market Shares Of Drug Products For Used To Treat
Huntington’s Disease, 2011
Figure 30 : Manufacturer/Distributor Market Shares Of Drugs Used To Treat Corticobasal
Ganglionic Degeneration, 2011
Figure 31 : Global Sales Of Drug Products Used To Treat Movement Disorder Syndromes By
Disease Type, 2010-2017
Figure 32 : Global Market Shares Of Drug Products Used To Treat Movement Disorder
Syndromes By Disease Type, 2011
Region, 2010-2017
Syndromes By Region, 2011
Figure 35 : Global Sales Of Drug Products Used To Treat Parkinson’s Disease By Region, 2010-

2017
Figure 36 : Global Sales Of Drug Products Used To Treat Multiple System Atrophy By Region,
2010-2017
Figure 37 : Global Sales Of Drug Products Used To Treat Progressive Supranuclear Palsy By
Region, 2010-2017
Figure 38 : Global Sales Of Drug Products Used To Treat Hallervorden-Spatz Disease By Region,
2010-2017
Technology, 2010-2017
Syndromes By Technology, 2011
Figure 41 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat Parkinson’s
Disease, 2011
Figure 42 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat Multiple
System Atrophy, 2011
Figure 43 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat Progressive
Supranuclear Palsy, 2011
Figure 44 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat Hallervorden-
Spatz Disease, 2011
Figure 45 : U.S. Patents On Drugs Used To Treat Syndromes Of Dementia And Movement
Disorders Issued Per Year, 2010—March 2012
Figure 46 : Percentage Of U.S. Patents On Drugs Used To Treat Syndromes Of Dementia And
Movement Disorders Issued Per Year, 2010-March 2012
Figure 47 : U.S. Patents On Drugs Used To Treat Syndromes Of Dementia And Movement
Disorders By Category Of Disease, 2010-March 2012
Figure 48 : U.S. Patents On Drugs Used To Treat Syndromes Of Dementia By
Clinical/Pathological Feature, 2010-March 2012*
Figure 49 : U.S. Patents On Drugs Used To Treat Movement Disorder Syndromes By Disease
Type, 2010-March 2012
Figure 50 : U.S. Patents On Drugs Used To Treat Syndromes Of Dementia (Progressive
Dementia) By Patent Holder’s Country, 2010-March 2012
Figure 51 : U.S. Patents On Drugs Used To Treat Movement Disorder Syndromes By Patent

Contact: sales@reportsandreports.com for more information.

Global Markets for Treatments for Syndromes of Dementia and Movement Disorders

Recommended

Recommended

More Related Content

Viewers also liked

Viewers also liked (7)

Global Markets for Treatments for Syndromes of Dementia and Movement Disorders